Peter Vuylsteke - Concepedia

Author

Peter Vuylsteke

Also Known As

Ana Montes, Colombo, N, Ignace Vergote, Lionel D'Hondt, P VUYLSTEKE, P Vuylsteke, P. A. van Dam, P. Vuylsteke, Peter VUYLSTEKE, Peter Vuylsteke

305

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Institut Jules Bordet KU Leuven Université Libre de Bruxelles UCLouvain CHU Dinant Godinne UCL Namur

About

Peter Vuylsteke is an author at Institut Jules Bordet specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	32	3.4K
2	Health Sciences	6	6	1K
3	Nursing	2	2	176
4	Biostatistics	1	1	336
5	Endocrinology	1	1	17

Peter Vuylsteke

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, New England Journal of Medicine	2016	2K
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, The Lancet Oncology MedicineRandomised Phase 2GynecologyCancer TreatmentOncology	2014	540
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial José Baselga, Seock‐Ah Im, Hiroji Iwata, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyClinical TrialsGynecology	2017	532
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response Evandro de Azambuja, Andrew Holmes, Martine Piccart, The Lancet Oncology Survival OutcomesBreast OncologyMedicinePathologyPathological Complete Response	2014	452
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age Martine Piccart, Laura van ‘t Veer, Coralie Poncet, The Lancet Oncology Breast OncologyEarly Breast CancerMedicine70-Gene SignatureClinical Trials	2021	336
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study James Glasbey, Adesoji Ademuyiwa, Adewale Adisa, The Lancet Oncology	2021	280
<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO Géraldine Gebhart, Cristina Gámez‐Cenzano, Eileen Holmes, Journal of Nuclear Medicine	2013	157
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) Fátima Cardoso, Shani Paluch–Shimon, Eva Schumacher-Wulf, The Breast Surgical OncologyBreast OncologyCancer ManagementSurgeryGynecology Oncology	2024	155
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum Bradley J. Monk, Rachel N. Grisham, Susana Banerjee, Journal of Clinical Oncology	2020	144
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, The Lancet Oncology Breast OncologyOncologyMetronomic TherapyBreast CancerMetronomic Chemotherapy	2018	126

Page 1